SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CervoMed Presents Interim Data Showing Biomarker Reduction With Neflamapimod

Twenty-four-week interim data showed an exposure-dependent reduction in neurofilament light chain, a biomarker of neuronal damage. Full biomarker and clinical data are expected in the first quarter.

CRVO

Related stories